This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Katpally, U.
Right arrow Articles by Smith, T. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katpally, U.
Right arrow Articles by Smith, T. J.

 Previous Article  |  Next Article 

Journal of Virology, July 2009, p. 7040-7048, Vol. 83, No. 14
0022-538X/09/$08.00+0     doi:10.1128/JVI.00557-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Antibodies to the Buried N Terminus of Rhinovirus VP4 Exhibit Cross-Serotypic Neutralization{triangledown}

Umesh Katpally,1 Tong-Ming Fu,2 Daniel C. Freed,2 Danilo R. Casimiro,2 and Thomas J. Smith1*

The Donald Danforth Plant Science Center, 975 North Warson Road, St. Louis, Missouri 63132,1 Vaccine Basic Research, Merck Research Laboratories, West Point, Pennsylvania 194862

Received 18 March 2009/ Accepted 20 April 2009

Development of a vaccine for the common cold has been thwarted by the fact that there are more than 100 serotypes of human rhinovirus (HRV). We previously demonstrated that the HRV14 capsid is dynamic and transiently displays the buried N termini of viral protein 1 (VP1) and VP4. Here, further evidence for this "breathing" phenomenon is presented, using antibodies to several peptides representing the N terminus of VP4. The antibodies form stable complexes with intact HRV14 virions and neutralize infectivity. Since this region of VP4 is highly conserved among all of the rhinoviruses, antiviral activity by these anti-VP4 antibodies is cross-serotypic. The antibodies inhibit HRV16 infectivity in a temperature- and time-dependent manner consistent with the breathing behavior. Monoclonal and polyclonal antibodies raised against the 30-residue peptide do not react with peptides shorter than 24 residues, suggesting that these peptides are adopting three-dimensional conformations that are highly dependent upon the length of the peptide. Furthermore, there is evidence that the N termini of VP4 are interacting with each other upon extrusion from the capsid. A Ser5Cys mutation in VP4 yields an infectious virus that forms cysteine cross-links in VP4 when the virus is incubated at room temperature but not at 4°C. The fact that all of the VP4s are involved in this cross-linking process strongly suggests that VP4 forms specific oligomers upon extrusion. Together these results suggest that it may be possible to develop a pan-serotypic peptide vaccine to HRV, but its design will likely require details about the oligomeric structure of the exposed termini.

* Corresponding author. Mailing address: The Donald Danforth Plant Science Center, 975 North Warson Road, St. Louis, MO 63132. Phone: (314) 587-1451. Fax: (314) 587-1551. E-mail: tsmith{at}danforthcenter.org

{triangledown} Published ahead of print on 29 April 2009.

Journal of Virology, July 2009, p. 7040-7048, Vol. 83, No. 14
0022-538X/09/$08.00+0     doi:10.1128/JVI.00557-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»